Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318525 | 1.00 | POLB (0.47) | POLBSMN1; SMN2CTSKUSP2FOLH1 | |
| SCHEMBL4318518 | 1.00 | POLB (0.47) | POLBSMN1; SMN2CTSKUSP2FOLH1 | |
| SCHEMBL4327583 | 1.00 | POLB (0.47) | POLBSMN1; SMN2CTSKUSP2FOLH1 | |
| SCHEMBL4327587 | 1.00 | POLB (0.47) | POLBSMN1; SMN2CTSKUSP2FOLH1 | |
| SCHEMBL4318466 | 0.85 | POLB (0.43) | POLBSMN1; SMN2CTSK | |
| SCHEMBL13784255 | 0.85 | POLB (0.43) | POLBSMN1; SMN2CTSK | |
| SCHEMBL4318468 | 0.85 | POLB (0.43) | POLBSMN1; SMN2CTSK | |
| SCHEMBL4318463 | 0.85 | POLB (0.43) | POLBSMN1; SMN2CTSK | |
| SCHEMBL4318551 | 0.78 | TAS1R3 (0.61) | CTSK | |
| SCHEMBL4314731 | 0.78 | TAS1R3 (0.61) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | POLB 3435/4885SMN1; SMN2 4497/4885CTSK 1/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | POLB 3478/4885SMN1; SMN2 4434/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.